戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ht in the former placebo group; all received riociguat).
2 ing the soluble guanylate cyclase stimulator riociguat.
3 lmonary endarterectomy to receive placebo or riociguat.
4 herapy with the guanylate cyclase stimulator riociguat.
5 bel extension in which all patients received riociguat.
6  double-blind treatment with oral placebo or riociguat (0.5, 1, or 2 mg 3 times daily) for 16 weeks i
7 interactive voice and web response system to riociguat (0.5-2.5 mg three times daily) or placebo for
8 ipants (40%) had taken natalizumab, 10 (16%) riociguat, 15 (24%) sodium oxybate, and 10 (16%) vigabat
9 ase in mean pulmonary artery pressure in the riociguat 2 mg group (-6.1+/-1.3 mm Hg; P<0.0001 versus
10 3; P=0.0002) were significantly reduced with riociguat 2 mg.
11  were randomly allocated to treatment (73 to riociguat, 74 to placebo).
12                       We aimed to examine if riociguat, a direct stimulator of the nitric oxide recep
13                                              Riociguat, a member of a new class of compounds (soluble
14                         We hypothesized that riociguat, a novel soluble guanylate cyclase stimulator,
15 e show that the guanylate cyclase activator, riociguat, a novel treatment for PAH, enhances current t
16                                              Riociguat, a soluble guanylate cyclase stimulator, has b
17 ronic thromboembolic pulmonary hypertension, riociguat, a stimulator of soluble guanylate cyclase, ha
18 ry vascular resistance >4 WU received add-on riociguat after BPA (n=18) or add-on BPA after riociguat
19 the functional complex, and cotreatment with riociguat, an FDA-approved sGC agonist, evoked redox str
20 ata for the primary end point assessment (49 riociguat and 51 BPA).
21                                              Riociguat and balloon pulmonary angioplasty (BPA) improv
22                                         Both riociguat and BPA are effective in improving RV afterloa
23          Importantly, comparative effects of riociguat and BPA on different components of right ventr
24 and RV afterload improved significantly with riociguat and BPA, and the relative changes in RV afterl
25  protective effects triggered by cinaciguat, riociguat, and different phosphodiesterase-5 inhibitors
26 o group) and mortality in patients receiving riociguat, and the absence of efficacy signals in the ri
27                                              Riociguat can be repurposed to overcome CRPC, with nonin
28                                              Riociguat decreased castration-resistant tumor growth an
29 imilar to the other activators investigated, riociguat did not have any effect on current through mut
30                                              Riociguat did not improve 6MWD versus placebo at 26 week
31             The guanylate cyclase activator, riociguat, enhanced current through WT TASK-1 channels;
32                                              Riociguat enhancement of current through TASK-1 channels
33 of CHEST-2, where most patients had received riociguat for at least 2 years.
34 erious adverse event was 22.7% (n=15) in the riociguat group and 31.3% (n=20) in the placebo group (d
35 nts in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group).
36 tance decreased by 226 dyn.sec.cm(-5) in the riociguat group and increased by 23 dyn.sec.cm(-5) in th
37 in study: 27 [37%] of 73 participants in the riociguat group vs 17 [23%] of 74 in the placebo group)
38 g disease (main study: six [8%] of 73 in the riociguat group vs five [7%] of 74 in the placebo group)
39 ere peripheral oedema (16 [22%] of 73 in the riociguat group vs seven [9%] of 74 in the placebo group
40 tance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m
41 nine died in the extension phase (one in the riociguat group, eight in the former placebo group; all
42 atients died in the main study (eight in the riociguat group, three in the placebo group), and nine d
43 , and the absence of efficacy signals in the riociguat group.
44 ed cardiac output was the main driver in the riociguat group.
45 ical efficacy endpoints, participants taking riociguat had a blood pressure of -8.20 mm Hg (-10.48 to
46   Prespecified subgroup analyses showed that riociguat improved the 6-minute walk distance both in pa
47 riociguat monotherapy and 199 were receiving riociguat in combination with endothelin receptor antago
48 ry arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg
49 three times daily (2.5 mg-maximum group), or riociguat in individually adjusted doses that were cappe
50 ding pharmacological profile, application of riociguat in other cardiovascular indications is limited
51 aimed to evaluate the efficacy and safety of riociguat in patients with PH-IIP.
52 tries to evaluate the efficacy and safety of riociguat in patients with PH-IIP.
53   These results support the long-term use of riociguat in patients with pulmonary arterial hypertensi
54 th pulmonary arterial hypertension receiving riociguat in the PATENT-2 study.
55                        All patients received riociguat individually adjusted to a maximum dose of 2.5
56 ension study, in which all patients received riociguat individually adjusted to a maximum dose of 2.5
57                                              Riociguat may be used long term in patients with CTEPH.
58 igation for ablation or medical therapy with riociguat (MED group; n = 25).
59 ATENT-2, of whom 197 patients were receiving riociguat monotherapy and 199 were receiving riociguat i
60 ociguat after BPA (n=18) or add-on BPA after riociguat (n=36) and were included in an ancillary 26-we
61 articipants were randomly assigned to either riociguat (n=66) or placebo (n=64).
62 were randomly assigned 1:1 to receive either riociguat or matching placebo via a web-based system to
63 iological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol
64                                              Riociguat reduced the Minnesota Living With Heart Failur
65                                              Riociguat should not be used in patients with PH-IIP.
66                                              Riociguat significantly improved exercise capacity and p
67                                              Riociguat significantly improved exercise capacity and s
68 %) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events.
69 ence and can be stimulated with FDA-approved riociguat to resensitize resistant tumors to androgen de
70                                              Riociguat treatment reorganized the tumor vasculature an
71 st patients had received at least 2 years of riociguat treatment.
72 ysis including patients from the RACE trial (Riociguat Versus Balloon Pulmonary Angioplasty in Non-Op
73                                              Riociguat was also associated with significant improveme
74                     In patients with PH-IIP, riociguat was associated with increased serious adverse
75 s soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment o
76                                              Riociguat was safe and had a significant haemodynamic ef
77                                              Riociguat was well tolerated by most patients and no new
78                                              Riociguat was well tolerated in PATENT-2.
79  primary end point of the study was not met, riociguat was well tolerated in patients with pulmonary
80 male patients of reproductive age prescribed riociguat were included.